Phaseline

Companies › Birch BioMed

Birch BioMed: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Immunology; next expected readout Sep 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
FS2
Kynurenic acid, aryl hydrocarbon receptor (AhR) agonist
AHRPhase 2Burn ScarSep 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06807021FS2Phase 2Burn ScarImmunologySep 2027

Targets

AHR (1)

Companies with the same targets

Organon and

Companies built like this

Toll Biotech Co. Ltd. (Beijing) Ventus Therapeutics U.S. Navigator Medicines OrthoTrophix Resolve Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.